Article
Ascidian Therapeutics rises from ATP's ocean floor with $50M and Dyne's former CEO
Rating:
0.0
Views:
65
Likes:
1
Library:
1
Inspired by ocean “sea squirts,” Ascidian Therapeutics is floating to the surface with $50 million in series A treasure to fund its ambitions to rewrite RNA for therapeutic benefit. | Ascidian Therapeutics is launching up from the ocean floor with $50 million in series A funds. The company's primary focus is the continued development of its lead asset targeting ABCA4 gene mutations.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value